E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/21/2014 in the Prospect News PIPE Daily.

Ruthigen prices $19.21 million initial public sale at $7.25 per unit

Bookrunner Dawson James raises funds for clinical trial of RUT58-60

By Devika Patel

Knoxville, Tenn., March 21 - Ruthigen, Inc. priced its $19.21 million initial public offering of units with a $2.88 million greenshoe, according to a prospectus filed Friday with the Securities and Exchange Commission. The deal was announced on Aug. 8 as a stock offering.

The company will sell 2.65 million units of one common share and one series A warrant at $7.25 per unit. Each two-year series A warrant is exercisable for a unit of one common share and one series B warrant at $7.25 per unit. Each five-year series B warrant is exercisable for one common share at $9.0625.

Dawson James Securities, Inc. is the bookrunning manager.

Settlement is expected March 26.

Proceeds will be used for a planned phase 1/2 clinical trial of RUT58-60, research and development activities, to establish an independent research facility, for milestone payments to Oculus, general corporate purposes and working capital.

The Santa Rosa, Calif., biopharmaceutical company is a subsidiary of Oculus Innovative Sciences, Inc. The company's expects its shares will trade on the Nasdaq under the symbol "RTGN."

Issuer:Ruthigen, Inc.
Issue:Units of one common share and one series A warrant
Amount:$19,212,500
Greenshoe:$2,881,875
Units:2.65 million
Price:$7.25
Warrants:One series A warrant per unit, one series B warrant upon conversion
Warrant expiration:Two years, five years
Warrant strike price:$7.25, $9.0625
Bookrunner:Dawson James Securities, Inc.
Announcement date:Aug. 8
Pricing date:March 21
Settlement date:March 26
Stock symbol:Nasdaq: RTGN

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.